Belimumab (Benlysta)

Benlysta (belimumab) is covered for adults with active, autoantibody‑positive systemic lupus erythematosus receiving standard therapy but is excluded for severe active lupus nephritis or severe active CNS lupus, cannot be used with other biologics or IV cyclophosphamide, and has no approved off‑label indications. Approval (up to 12 months) requires documentation of SLE diagnosis, autoantibody positivity (eg, ANA, anti‑dsDNA, anti‑Sm), current/recent standard therapy, confirmation that excluded conditions and prohibited combination therapies are absent, and patient age.

"For the treatment of an adult with active, autoantibody-positive, systemic lupus erythematosus who is receiving standard therapy"

Sign up to see full coverage criteria, indications, and limitations.